Pharmacotherapy: Obesity Breakthroughs

Learning Objectives:

• At the end of the presentation attendees will be able to discuss the following breakthroughs:
  • Tirzepatide treatment for adult obesity shows >90% can achieve >10% weight loss;
  • Semaglutide gets FDA indication for obesity management in children age 12-18;
  • Semaglutide for obesity achieves indication for secondary prevention of cv events;
  • Semaglutide shows promise in HFpEF and chronic kidney disease;
  • Obesity drug development uses GLP-1 backbone with 4 new compounds in phase 3; and
  • Post-marketing surveillance posts reassuring